Skip to main content
. 2023 Aug 22;14:5111. doi: 10.1038/s41467-023-40814-9

Fig. 3. CISP targeted to tumors in vivo.

Fig. 3

a, b Fluorescence images of B16F10 tumors in mice treated with free DiD, QFN717, nCSP, nCISP, and CISP (a) and the mean fluorescence intensity of DiD in tumors (b) (n = 3 mice). c, d Fluorescence images of B16F10 tumors at 6 h post injection of nCSP, nCISP (20 mM), and nCISP (30 mM) (c), and the mean fluorescence intensity of DiD in tumors (d) (n = 5 mice). e Concentration of SR-717 in tumors detected by LC-MS/MS (n = 4 mice). f Representative images of QFN core, PD-L1, and LAMP1 in tumors and the fluorescence intensity on the arrow line (n = 3 independent samples). Scale bar = 10 μm. Data represent mean ± SEM (b, d, e). Statistical significance was determined by one-way ANOVA test in b, d, e, and it was two-sided and adjustments were made for multiple comparisons. The experiments for a, f were repeated three times independently with similar results. Source data are provided as a Source Data file. MFI mean fluorescence intensity, QFN Quercetin-ferrum nanoparticles, QFN717 QFN loaded with SR-717, nCSP normal-Cholesterol cell membrane-coated QFN717, CSP low-cholesterol membrane-coated QFN717, nCISP normal-Cholesterol cell membrane-coated ICB agent and QFN717, CISP low-cholesterol membrane-coated ICB agent and QFN717, CISP (20 mM) low-cholesterol membrane (treated with 20 mM β-CD) coated ICB agent and QFN717, CISP (30 mM) low-cholesterol membrane (treated with 30 mM β-CD) coated ICB agent and QFN717.